Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

European Launch of Proxima

18th Mar 2015 07:00

RNS Number : 7095H
Sphere Medical Holding plc
18 March 2015
 

18 March 2015

 

Sphere Medical Holding plc

European Launch of Proxima

 

- Proxima supports rapid and frequent bedside blood gas measurements

- European launch on target and builds on UK launch

 

 

Cambridge, UK, 18 March 2015: Sphere Medical Holding plc (AIM: SPHR.L), ("Sphere Medical" or the "Company"), a leading provider of innovative monitoring and diagnostic devices for the critical care setting, today announces the European launch of Proxima, its cutting edge in-line patient dedicated arterial blood gas analyser, at the 35th International Symposium on Intensive Care and Emergency Medicine (ISICEM), Brussels, 17-20 March.

 

Sales will be initially targeted within the Netherlands, Belgium and German markets through a small, direct sales team. Learnings from the recent UK launch supported by the considerable experience of the Medical Advisory Board are proving instrumental in facilitating entry into these important new markets.

 

Sphere Medical's Chief Executive Officer, Wolfgang Rencken, said: "Europe represents a significant opportunity for sales of Proxima. The support of our hugely experienced Medical Advisory Board and their endorsement of Proxima, will assist with the sales effort and we look forward to providing further updates on developments."

 

Commenting on the clinical importance of Proxima, Professor Michael Quintel, Director of the Department of Anaesthesiology, Emergency and Intensive Care Medicine at the University of Göttingen, Germany, said: "Proxima addresses some important issues in the management of unstable critically ill patients. The launch of this product offers some exiting new opportunities for intensive care medicine in Germany."

 

The Proxima system will be displayed at Stand 1.35 at ISICEM 2015.

 

For further information, please contact:

 

Sphere Medical Holding plc Tel: +44 (0)1223 875 222

Dr Wolfgang Rencken, Chief Executive Officer

Matthew Hall, Chief Financial Officer

 

Peel Hunt LLP Tel: +44 (0)20 7418 8900

James Steel

Clare Terlouw

Jock Maxwell Macdonald

 

finnCap Tel: +44 (0)20 7220 0500

Geoff Nash / Simon Hicks

Stephen Norcross

 

Consilium Strategic Communications Tel: +44 (0)20 3709 5700

Mary-Jane Elliott [email protected]

Matthew Neal

Ivar Milligan

 

Notes for Editors

About Sphere Medical (AIM: SPHR.L)

Sphere Medical is a medical device company developing a range of innovative monitoring and diagnostic devices designed to significantly improve patient care.

 

Sphere Medical's vision is to become a leading solution provider to the critical care market offering innovative, near real time, point of care diagnostic and monitoring products to enable closer control of therapeutic response and improve patient outcomes and reduce the overall cost of care.

 

The Company's strategy is focused on developing the Proxima (CE marked device) platform for measuring blood gases, electrolytes and metabolites. The Company is already marketing its Proxima product directly to the critical care market, which includes the ICU and OR, with a dedicated field sales force in the UK. Sphere's marketing now follows in Germany and Benelux via a direct sales force in Europe and Sphere will work with partners for worldwide distribution.

 

Sphere Medical's products deliver near real time analysis of blood gases, electrolytes and drug levels with laboratory accuracy, at the patient's bedside. Sphere Medical's products can be used in a wide range of medical applications, enabling faster clinical decision making and improved patient outcomes, whilst reducing costs for healthcare payers.

 

Sphere Medical entered into a collaboration agreement with Ortho Clinical Diagnostics, Inc. in 2013 for the development of Proxima and enhancement of Sphere's operational and production capabilities.

 

Sphere Medical has a number of partnerships with industry leading medical device companies and received a strategic investment from Ortho Clinical Diagnostics (now part of Carlyle Group). Other significant investors include Life Sciences Partners (LSP Life Sciences Fund).

 

For further information, please visit www.spheremedical.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCDDLFFEXFXBBD

Related Shares:

Sphere Medical Holding
FTSE 100 Latest
Value8,809.74
Change53.53